Mei Wang1, Yun-Hai Gao2, Jie Xu3, Yuan Chi4, Xiao-Bing Wei5, George Lewith6, Jian-Ping Liu7. 1. School of Preclinical Medicine, Liaoning University of Traditional Chinese Medicine, 79 Chong Shan Dong Lu, Huanggu District, Shenyang 110847, China. Electronic address: linhan616@126.com. 2. Department of General Surgery, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Bei Ling Street, Huanggu District, Shenyang 110032, China. Electronic address: gaoyh-573@163.com. 3. School of Preclinical Medicine, Liaoning University of Traditional Chinese Medicine, 79 Chong Shan Dong Lu, Huanggu District, Shenyang 110847, China. Electronic address: xujie729@yeah.net. 4. School of Preclinical Medicine, Liaoning University of Traditional Chinese Medicine, 79 Chong Shan Dong Lu, Huanggu District, Shenyang 110847, China. Electronic address: chemcy@mail.dlut.edu.cn. 5. Department of General Surgery, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, 33 Bei Ling Street, Huanggu District, Shenyang 110032, China. Electronic address: weixiaobing1314@126.com. 6. Primary Care, Faculty of Medicine, University of Southampton, Hampshire SO16 5ST, UK. Electronic address: glewith@scmrt.org.uk. 7. School of Preclinical Medicine, Liaoning University of Traditional Chinese Medicine, 79 Chong Shan Dong Lu, Huanggu District, Shenyang 110847, China; Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing 100029, China. Electronic address: jianping_l@hotmail.com.
Abstract
OBJECTIVE: To evaluate the preventive effect of Zusanli (ST36) acupoint injections with various agents, for postoperative ileus (POI). METHODS: We searched electronic databases for randomized controlled trials from inception to 1st February 2015 evaluating ST36 acupoint injection for preventing POI. Revman 5.2.0 was used for data analysis with effect estimates presented as mean difference (MD) with 95% confidence interval (CI). Statistical heterogeneity was tested using I(2) (defined as significant if I(2)>75%). We used a random effects model (REM) for pooling data with significant heterogeneity. RESULTS: Thirty trials involving 2967 participants were included. All trials were assessed as high risk of bias (poor methodological quality). For time to first flatus, meta-analysis favored ST36 acupoint injection of neostigmine (MD -20.70h, 95% CI -25.53 to -15.87, 15 trials, I(2)=98%, REM), vitamin B1 (MD -11.22h, 95% CI -17.01 to -5.43, 5 trials, I(2)=98%, REM), and metoclopramide (MD -15.65h, 95% CI -24.77 to -6.53, 3 trials, I(2)=94%, REM) compared to usual care alone. Meta-analysis of vitamin B1 favored ST36 acupoint injection compared to intra-muscular injection (MD -17.21h, 95% CI -21.05 to -13.36, 4 trials, I(2)=89%, REM). Similarly, for time to bowel sounds recovery and first defecation, ST36 acupoint injection also showed positive effects. CONCLUSIONS: ST36 acupoint injections with various agents may have a preventive effect for POI. Safety is inconclusive as few of included trials reported adverse events. Due to the poor methodological quality and likely publication bias further robust clinical trials are required to arrive at a definitive conclusion.
OBJECTIVE: To evaluate the preventive effect of Zusanli (ST36) acupoint injections with various agents, for postoperative ileus (POI). METHODS: We searched electronic databases for randomized controlled trials from inception to 1st February 2015 evaluating ST36 acupoint injection for preventing POI. Revman 5.2.0 was used for data analysis with effect estimates presented as mean difference (MD) with 95% confidence interval (CI). Statistical heterogeneity was tested using I(2) (defined as significant if I(2)>75%). We used a random effects model (REM) for pooling data with significant heterogeneity. RESULTS: Thirty trials involving 2967 participants were included. All trials were assessed as high risk of bias (poor methodological quality). For time to first flatus, meta-analysis favored ST36 acupoint injection of neostigmine (MD -20.70h, 95% CI -25.53 to -15.87, 15 trials, I(2)=98%, REM), vitamin B1 (MD -11.22h, 95% CI -17.01 to -5.43, 5 trials, I(2)=98%, REM), and metoclopramide (MD -15.65h, 95% CI -24.77 to -6.53, 3 trials, I(2)=94%, REM) compared to usual care alone. Meta-analysis of vitamin B1 favored ST36 acupoint injection compared to intra-muscular injection (MD -17.21h, 95% CI -21.05 to -13.36, 4 trials, I(2)=89%, REM). Similarly, for time to bowel sounds recovery and first defecation, ST36 acupoint injection also showed positive effects. CONCLUSIONS: ST36 acupoint injections with various agents may have a preventive effect for POI. Safety is inconclusive as few of included trials reported adverse events. Due to the poor methodological quality and likely publication bias further robust clinical trials are required to arrive at a definitive conclusion.
Authors: S M M de Castro; J W van den Esschert; N T van Heek; S Dalhuisen; M J W Koelemay; O R C Busch; D J Gouma Journal: Dig Surg Date: 2008-02-21 Impact factor: 2.588
Authors: Dieter Melchart; Andrea Streng; Andrea Hoppe; Benno Brinkhaus; Claudia Witt; Stefan Wagenpfeil; Volker Pfaffenrath; Michael Hammes; Josef Hummelsberger; Dominik Irnich; Wolfgang Weidenhammer; Stefan N Willich; Klaus Linde Journal: BMJ Date: 2005-07-29
Authors: Ma Peihong; Qu Yuzhu; Yin Tao; He Zhaoxuan; Cheng Shirui; Teng Yuke; Xie Kunnan; Li Shenghong; Sun Ruirui; Zeng Fang Journal: Front Neurosci Date: 2021-05-20 Impact factor: 4.677